Pharma and Biotech Leaders to Converge in Shanghai

Tuesday, November 10, 2009 General News J E 4
SHANGHAI, Nov. 9 The pharma and biotech sectors areat a pivotal point in their evolution. The companies are facing significantpressure to change with thinning pipelines, skyrocketing R&D costs, calls forlower prices and a greater regulatory burden, these conditions together withthe financial crisis have made the work of creating new drugs harder than ever.Big pharmaceutical companies are being forced to globalize their R&Doperations, especially to emerging markets.

Under this background, leaders of pharma and biotech companies from aroundthe world will gather in Shanghai on March 4-5, 2010 at Asia Pharma R&DLeaders 2010 for strategies to capitalize on the enormous opportunity thebooming Asia Market provides.

This event focuses on the operational, regulatory, and strategicchallenges of outsourcing your drug discovery work to Asia.

Hear from distinguished industry experts at Asia Pharma R&D Leaders 2010.Some of this year's highlighted topics include:

Plus, the event sets up an effective platform for you to meet face to facewith a variety of Asia's local CROs and leading clinical practitioners todiscuss the specifics of your outsourcing requirements.

An international audience consisting of senior-level pharma and biotechexecutives from the R&D, clinical development, business development, globalmarket access, licensing, and regulatory affairs functions will be inattendance. For the full program and list of companies scheduled to attend,please visit the event website at .

For more information on registration and sponsoring/exhibiting, pleasecontact:

Daniel Chen

Tel: +86-21-3251-6110

Email: Partnering for innovation in Asia, new collaboration opportunities with big pharma -- Laurent Bertin, Vice President, R&D External Innovation, Sanofi- Aventis -- Hans-Jochiam Bohm, Head of Global Chemistry, Hoffman La-Roche -- Daniel Grant, Head of Strategic Alliances, Pfizer Australia -- Pierre Desmons, Director, Head of Development Partnerships, GlaxoSmithKline Biologicals -- Regulatory updates in China and how FDA is making sure the quality of outsourced work -- Christopher Hickey, Country Director (China), U.S. Food and Drug Administration -- Successful stories of R&D operation management in Asia and Do's & Don'ts in outsourcing -- Steve Yang, Head of Research Asia Global R&D, Pfizer -- Lily Lee, Senior Vice President and Head of Pharmaceutical R&D Asia, Johnson and Johnson -- Li Chen, Chief Scientific Officer Roche R&D China -- Tony Zhang, Managing Director and Site Head of China, Eli Lilly Global R&D -- Samantha Du, CEO, Hutchison MediPharma -- Richard Wang, Director, Strategic Alliance and Collaboration for Asia, AstraZeneca -- Yoshiki Nishikawa, Director of Kobe Pharma Research Institute Nippon, Boehringer Ingelheim

SOURCE Global Leaders Institute


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Give an Hour(TM) Partners with American Red Cross ...
Cardiome Reports Third Quarter Results